Pharma's Almanac TV
PA TV
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Company Info
Headquarters
Number of Employees
Revenue (in millions)
Contact Info
Visit Website
Tagline
Overview
Company Services
Site Information
Contributors
Contributions
Partnership
Novavax Selects AGC Biologics to Manufacture Matrix-M Adjuvant for Novel COVID-19 Vaccine
PR-M06-20-NI-008
Expansion
AGC Biologics Expands Plasmid DNA Offering
PR-M12-19-NI-030
Antibody-Drug Conjugate
Fast-Tracking ADC Development and Commercialization
PAP-Q4-19-CL-003
Customer Centricity
Uniting Innovation and Customer-Centricity
PTV-M08-19-BIO-001
Customer Focus
Designing a Customer-Centric CDMO
PAP-Q2-2019-CL-003
Appointment
Dr. Gustavo Mahler Resigns as Chief Executive Officer of AGC Biologics, Patricio Massera to Succeed as CEO Effective May 1st, 2019
PR-M04-19-NI-032
Biologics Manufacturing
AGC Triples U.S. Biopharmaceutical Production Capacity
PR-M12-18-NI-066
Contract Manufacturing Needs
Meeting Biopharma Contract Manufacturing Needs with a Flexible Global Network
PAP-Q2-18-CL-006
Supply Agreement
AGC Biologics Enters into Commercial Supply Agreement with MacroGenics
PR-M05-18-NI-053
Commercial Manufacturing Agreement
AGC Biologics Enters into Commercial Manufacturing Agreement with Horizon Pharma plc
PR-M05-18-NI-036
Expanded Capacity
AGC Biologics Increases Footprint in Bothell, WA
PR-M04-18-NI-016
Expanded Capacity
AGC Biologics Expands Capacity at Berkeley, California Facility
PR-M03-18-NI-033
Merger
CMC Biologics Becomes AGC Biologics
PAO-M01-18-NI-032
Oncology
CMC Biologics Announces Agreement
PAO-M12-17-NI-032
Innovation
CMC and Trellis Agree to Develop mAb Therapies to Treat Viral, Bacterial Infections
PAO-M08-17-NI-010
Biologics
Achieving Continuous Downstream Bioprocessing
PAP-Q04-16-CL-009
Excipients
Quality by Design: Transforming 21st Century Pharmaceutical Manufacturing
PAP-Q03-16-CL-003
Biologics
Scale-Down Models: An Indispensable Tool to Biopharmaceutical Process Development
PAP-Q02-16-CL-008
CDMO
Advancing Biologics Development and Manufacturing
PAP-Q1-16-CL-011
